Antibe Therapeutics Inc(Pre-Merger) T.ATE

RE:New indications IP

[MrMugsy]

Correct.

Looks like it is also know as ATB-344 or an H2S releasing Indomethacin product.
ATB-344 was initially intended for gout and the market size was about $500M (2013).

For the past 2 years we've been waiting for word of a respiratory/COVID drug - guessing 344 is the winner over Regeneron and ATB-429 (if I recall from the patent).

Also - don't take my word for it as I don't know my chemistry - but - it does look like new H2S chemistry. 

I see an N-thiocarboxy design with minimal acute in vitro toxicity observed in multiple cell lines while longer-term toxicity in cancer cells (if related).  Tuning the H2S release rate might be easier with this design. 

Will see ... if they ever update us.

Then again - I think they owe us a lot of other things before we get any information on this one.  All in my opinion.